Nationwide trends and outcomes of neoadjuvant chemotherapy in pancreatic cancer – an analysis of the Swedish national pancreatic cancer registry

References

• Goldstein D, El-Maraghi RH, Hammel P, et al. nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial. J Natl Cancer Inst. 2015:107(2).
   Google Scholar
• Kleeff J, Korc M, Apte M, et al. Pancreatic cancer. Nat Rev Dis Primers. 2016;2:16022.
   PubMed Web of Science ®Google Scholar
• Chandrasegaram MD, Goldstein D, Simes J, et al. Meta-analysis of radical resection rates and margin assessment in pancreatic cancer. Br J Surg. 2015;102(12):1459–1472.
   PubMed Web of Science ®Google Scholar
• Hank T, Hinz U, Tarantino I, et al. Validation of at least 1 mm as cut-off for resection margins for pancreatic adenocarcinoma of the body and tail. Br J Surg. 2018;105(9):1171–1181.
   PubMed Web of Science ®Google Scholar
• Oettle H, Neuhaus P, Hochhaus A, et al. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. J Am Med Assoc. 2013;310(14):1473–1481.
   PubMed Web of Science ®Google Scholar
• Ferrone CR, Marchegiani G, Hong TS, et al. Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer. Ann Surg. 2015;261(1):12–17.
   PubMed Web of Science ®Google Scholar
• Wagner M, Antunes C, Pietrasz D, et al. CT evaluation after neoadjuvant FOLFIRINOX chemotherapy for borderline and locally advanced pancreatic adenocarcinoma. Eur Radiol. 2017;27(7):3104–3116.
   PubMed Web of Science ®Google Scholar
• Labori KJ, Lassen K, Hoem D, et al. Neoadjuvant chemotherapy versus surgery first for resectable pancreatic cancer (Norwegian pancreatic cancer trial - 1 (NorPACT-1)) – study protocol for a national multicentre randomized controlled trial. BMC Surg. 2017;17(1):94.
   PubMed Web of Science ®Google Scholar
• Ettrich TJ, Berger AW, Perkhofer L, et al. Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer - the NEONAX trial (AIO-PAK-0313), a prospective, randomized, controlled, phase II study of the AIO pancreatic cancer group. BMC Cancer. 2018;18(1):1298.
   PubMed Web of Science ®Google Scholar
• Schwarz L, Vernerey D, Bachet JB, et al. Resectable pancreatic adenocarcinoma neo-adjuvant FOLF(IRIN)OX-based chemotherapy - a multicenter, non-comparative, randomized, phase II trial (PANACHE01-PRODIGE48 study). BMC Cancer. 2018;18(1):762.
   PubMed Web of Science ®Google Scholar
• Katz MHG, Ou FS, Herman JM, Alliance for Clinical Trials on Oncology, et al. Alliance for clinical trials in oncology (ALLIANCE) trial A021501: preoperative extended chemotherapy vs. chemotherapy plus hypofractionated radiation therapy for borderline resectable adenocarcinoma of the head of the pancreas. BMC Cancer. 2017;17(1):505.
   PubMed Web of Science ®Google Scholar
• D'Angelo F, Antolino L, Farcomeni A, et al. Neoadjuvant treatment in pancreatic cancer: Evidence-based medicine? A systematic review and Meta-analysis. Med Oncol. 2017;34(5):85.
   PubMed Web of Science ®Google Scholar
• Versteijne E, Vogel JA, Besselink MG, Dutch Pancreatic Cancer Group, et al. Meta-analysis comparing upfront surgery with neoadjuvant treatment in patients with resectable or borderline resectable pancreatic cancer. Br J Surg. 2018;105(8):946–958.
   PubMed Web of Science ®Google Scholar
• Hartwig W, Werner J, Jager D, et al. Improvement of surgical results for pancreatic cancer. Lancet Oncol. 2013;14(11):e476–e485.
   PubMed Web of Science ®Google Scholar
• Bassi C, Marchegiani G, Dervenis C, et al. The 2016 update of the international study group (ISGPS) definition and grading of postoperative pancreatic fistula: 11 years After. Surgery. 2017;161(3):584–591.
   PubMed Web of Science ®Google Scholar
• Wente MN, Veit JA, Bassi C, et al. Postpancreatectomy hemorrhage (PPH): an international study group of pancreatic surgery (ISGPS) definition. Surgery. 2007;142(1):20–25.
   PubMed Web of Science ®Google Scholar
• Wente MN, Bassi C, Dervenis C, et al. Delayed gastric emptying (DGE) after pancreatic surgery: a suggested definition by the international study group of pancreatic surgery (ISGPS). Surgery. 2007;142(5):761–768.
   PubMed Web of Science ®Google Scholar
• Marchegiani G, Andrianello S, Nessi C, et al. Neoadjuvant therapy versus upfront resection for pancreatic cancer: the actual spectrum and clinical burden of postoperative complications. Ann Surg Oncol. 2018;25(3):626–637.
   PubMed Web of Science ®Google Scholar
• Cooper AB, Parmar AD, Riall TS, et al. Does the use of neoadjuvant therapy for pancreatic adenocarcinoma increase postoperative morbidity and mortality rates? J Gastrointest Surg. 2015;19(1):80–86. discussion 86–87
   PubMed Web of Science ®Google Scholar
• Czosnyka NM, Borgert AJ, Smith TJ. Pancreatic adenocarcinoma: effects of neoadjuvant therapy on post-pancreatectomy outcomes – an aAmericancollege of surgeons national surgical quality improvement program targeted variable review. HPB (Oxford. 2017;19(10):927–932.
   PubMed Web of Science ®Google Scholar
• Araujo RL, Gaujoux S, Huguet F, et al. Does pre-operative chemoradiation for initially unresectable or borderline resectable pancreatic adenocarcinoma increase post-operative morbidity? A case-matched analysis. HPB (Oxford). 2013;15(8):574–580.
   PubMed Web of Science ®Google Scholar
• Kamarajah SK, Bundred JR, Boyle C, et al. Impact of neoadjuvant therapy on post-operative pancreatic fistula: a systematic review and Meta-analysis. ANZ J Surg. 2020;90(11):2201–2210.
   PubMed Web of Science ®Google Scholar
• Tingstedt B, Andersson B, Jonsson C, et al. First results from the Swedish national pancreatic and periampullary cancer registry. HPB (Oxford). 2019;21(1):34–42.
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network. Pancreatic adenocarcinoma (version 1.2022). Available from https://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf.
   Google Scholar
• Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240(2):205–213.
   PubMed Web of Science ®Google Scholar
• Verma V, Li J, Lin C. Neoadjuvant therapy for pancreatic cancer: Systematic review of postoperative morbidity, mortality, and complications. Am J Clin Oncol. 2016;39(3):302–313.
   PubMed Web of Science ®Google Scholar
• van Dongen JC, Wismans LV, Suurmeijer JA, et al. The effect of preoperative chemotherapy and chemoradiotherapy on pancreatic fistula and other surgical complications after pancreatic resection: a systematic review and Meta-analysis of comparative studies. HPB (Oxford). 2021;23(9):1321–1331.
   PubMed Web of Science ®Google Scholar
• Cloyd JM, Heh V, Pawlik TM, et al. Neoadjuvant therapy for resectable and borderline resectable pancreatic cancer: a Meta-Analysis of randomized controlled trials. J Clin Med. 2020;(9):1129.
   Web of Science ®Google Scholar
• Janssen QP, Buettner S, Suker M, et al. Neoadjuvant FOLFIRINOX in patients with borderline resectable pancreatic cancer: a systematic review and Patient-Level Meta-Analysis. J Natl Cancer Inst. 2019;111(8):782–794.
   PubMedGoogle Scholar
• Casadei R, Di Marco M, Ricci C, et al. Neoadjuvant chemoradiotherapy and surgery versus surgery alone in resectable pancreatic cancer: a Single-Center prospective, randomized, controlled trial which failed to achieve accrual targets. J Gastrointest Surg. 2015;19(10):1802–1812.
   PubMed Web of Science ®Google Scholar
• Versteijne E, Suker M, Groothuis K, for the Dutch Pancreatic Cancer Group, et al. Preoperative chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer: Results of the dutch randomized phase III PREOPANC trial. J Clin Oncol. 2020;38(16):1763–1773.
   PubMed Web of Science ®Google Scholar
• Reni M, Balzano G, Zanon S, et al. Safety and efficacy of preoperative or postoperative chemotherapy for resectable pancreatic adenocarcinoma (PACT-15): a randomised, open-label, phase 2-3 trial. Lancet Gastroenterol Hepatol. 2018;3(6):413–423.
   PubMed Web of Science ®Google Scholar
• Golcher H, Brunner TB, Witzigmann H, et al. Neoadjuvant chemoradiation therapy with gemcitabine/cisplatin and surgery versus immediate surgery in resectable pancreatic cancer: results of the first prospective randomized phase II trial. Strahlenther Onkol. 2015;191(1):7–16.
   PubMed Web of Science ®Google Scholar
• Jang JY, Han Y, Lee H, et al. Oncological benefits of neoadjuvant chemoradiation with gemcitabine versus upfront surgery in patients with borderline resectable pancreatic cancer: a prospective, randomized, open-label, multicenter phase 2/3 trial. Ann Surg. 2018;268(2):215–222.
   PubMed Web of Science ®Google Scholar
• Rangelova E, Wefer A, Persson S, et al. Surgery improves survival after neoadjuvant therapy for borderline and locally advanced pancreatic cancer: a single institution experience. Ann Surg. 2021;273(3):579–586.
   PubMed Web of Science ®Google Scholar